SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
SAB BIO (Nasdaq: SABS) will participate in the Chardan 10th Annual Healthcare Conference on October 20, 2026, in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SAB BIO (Nasdaq: SABS) will participate in the Chardan 10th Annual Healthcare Conference on October 20, 2026, in New York.
Chief Executive Officer Samuel J. Reich will present in a fireside chat from 11:15 to 11:30 a.m. ET. Management will also be available for one-on-one meetings, which interested parties can arrange through their conference representative.
Key Terms
anti-thymocyte immunoglobulin medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Oct. 14, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the upcoming Chardan 10th Annual Healthcare Conference:
Date: October 20, 2026
Time: 11:15 - 11:30 a.m. ET
Format: Fireside Chat
Presenter: Samuel J. Reich, Chief Executive Officer
Location: New York, NY
Webcast: Register here
SAB BIO management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting. To access replay webcasts of investor events, please visit the Investors & Media section of SAB BIO’s website at www.sab.bio.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit www.sab.bio.
CONTACTS
Investor Relations:
Christine Ryan
ir@sab.bio
Media:
Sheila Carlson
media@sab.bio
